Orally administered liquid compositions

Details Orally administered liquid compositions Orally administered liquid compositions

2006-11-21

2006-11-21

Webman, Edward J. (Department: 1616)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Food or edible as carrier for pharmaceutical

C424S400000, C514S975000, C514S850000

Reexamination Certificate

active

07138133

ABSTRACT:
The present invention is an orally administered liquid pharmaceutical composition that demonstrates excellent physical stability while delivering concentrated levels of the pharmaceutical active(s). Specifically, these compositions for extended periods do not allow the active to precipitate or settle out of solution. Among the advantages of this invention is that the compositions do not require agitation/shaking prior to use as a method to re-suspend or dissolve active drug material to insure even and consistent dosing.

REFERENCES:
patent: 4100271 (1978-07-01), Krezanoski
patent: 4188373 (1980-02-01), Krezanoski
patent: 4474752 (1984-10-01), Haslam et al.
patent: 4474753 (1984-10-01), Haslam et al.
patent: 4478822 (1984-10-01), Haslam et al.
patent: 4511563 (1985-04-01), Schmolka
patent: 4673679 (1987-06-01), Aungst et al.
patent: 4810503 (1989-03-01), Carson et al.
patent: 4849418 (1989-07-01), Lohner et al.
patent: 4911926 (1990-03-01), Henry et al.
patent: 5030448 (1991-07-01), Hunter
patent: 5071644 (1991-12-01), Viegas et al.
patent: 5100898 (1992-03-01), Sorrentino
patent: 5135751 (1992-08-01), Henry et al.
patent: 5141961 (1992-08-01), Coapman
patent: 5143731 (1992-09-01), Viegas et al.
patent: 5183669 (1993-02-01), Hori
patent: 5256396 (1993-10-01), Piechota, Jr.
patent: 5292516 (1994-03-01), Viegas et al.
patent: 5298260 (1994-03-01), Viegas et al.
patent: 5300295 (1994-04-01), Viegas et al.
patent: 5306501 (1994-04-01), Viegas et al.
patent: 5318780 (1994-06-01), Viegas et al.
patent: 5346703 (1994-09-01), Viegas et al.
patent: 5360615 (1994-11-01), Yu et al.
patent: 5366735 (1994-11-01), Henry
patent: 5505961 (1996-04-01), Shelley et al.
patent: 5510389 (1996-04-01), Dhabhar
patent: 5527832 (1996-06-01), Chi et al.
patent: 5587175 (1996-12-01), Viegas et al.
patent: 5681576 (1997-10-01), Henry
patent: 5731007 (1998-03-01), Chung et al.
patent: 5820854 (1998-10-01), Glandorf
patent: 5869082 (1999-02-01), Dugger, III
patent: 5932589 (1999-08-01), Galli Angeli
patent: 5955098 (1999-09-01), Dugger, III
patent: 6110486 (2000-08-01), Dugger, III
patent: 6290986 (2001-09-01), Murdoch et al.
patent: 2238409 (1997-06-01), None
patent: 0211601 (1987-02-01), None
patent: 0386960 (1990-03-01), None
patent: 0439335 (1991-07-01), None
patent: 0551626 (1993-07-01), None
patent: WO 96/29986 (1996-10-01), None
patent: WO 97/10849 (1997-03-01), None
patent: WO 97/21441 (1997-06-01), None
patent: WO 97/38662 (1997-10-01), None
patent: WO 97/39742 (1997-10-01), None
patent: WO 98/06438 (1998-02-01), None
patent: WO 98/29127 (1998-07-01), None
patent: WO 99/16417 (1999-04-01), None
patent: WO 99/32152 (1999-07-01), None
patent: WO 00/21510 (2000-04-01), None
patent: WO 00/41693 (2000-07-01), None
patent: WO 01/19329 (2001-03-01), None
Weinberg et al., “Sublingual Absorption of Selected Opioid Analgesics”,Clin Pharmacol Ther, vol. 44, No. 3, 1988, pp. 335-342.
Harris et al., “Drug Delivery Via the Mucous Membranes of the Oral Cavity”,J. of Pharm Sciences, vol. 81, No. 1, 1992, pp. 1-10.
Salomonowitz et al., “Hydrophilic-Lipophilic Balance as Predictor of Mucus Coating with Barium Sulfate”Gastrointest Radio, vol. 11, 1986, pp. 93-96.
Chen-Chow et al., “In Vitro Release of Lidocaine From Pluronic F-127 Gels”,International Journal of Pharmaceutics, vol. 8, 1981, pp. 89-99.
Nurnberg et al., “Poloxamere-was ist das? Eigenschaften und Anwendungsmoglichkeiten”,Deutsche Apotheker Zeitung, vol. 129, No. 41, 1989, pp. 2183-2187.
Reeve, “The Poloxamers: Their Chemistry and Medical Applications”,Handbook of Biodegreadable Polymers, Editors: A. J. Domb, J. Kost and D. M. Wiseman, Harwood Acaemic Publishers, Chapter 12, pp. 231-249.
Juhasz et al., “Adhesion of Ploxamer 407 Formulations on Dog Ileal in Vitro”,Eur J Pharm Biopharm, vol. 37, No. 4, 1991, pp. 262-265.
Pandit et al., “Cosolvent Effects on the Gel Formation and Gel Melting Transitions of Pluronic F127 Gels”,Pharmaceutical Development and Technology, vol. 2, No. 2, 1997, pp. 181-184.
Gilbert et al., “Drug release from Pluronic F-127 gels”,International Journal of Pharmaceutics, vol. 32, 1986, pp. 223-228.
Lenaerts et al., “Temperature-dependent rheological behavior of Pluronic F-127 aqueouos solutions”,International Journal of Pharmaceutics, vol. 39, 1987, pp. 121-127.
Suh et al., “Pharmacokinetic and Local Tissue Disposition Studies of Naproxen Following Topical and Systemic Administration in Dogs and Rats”,Biopharmaceutics&Drug Disposition, vol. 18, No. 7, pp. 1997, 623-633.
Cappel et al., “Effect of nonionic surfactants on transdermal drug delivery: II. Poloxamer and poloxamine surfactants”,International Journal of Pharmaceutics, vol. 69, 1991, pp. 155-167.
Viegas et al., “Osmotic behavior of poloxamer 407 and other non-ionic surfactants in aqueous solutions”International Journal of Pharmaceutics, vol. 160, 1998, pp. 157-162.
Lu et al., “Diffusion studies of methotrexate in Carbopol and Poloxamer gels”,International Journal of Pharmaceutics, vol. 160, 1998, pp. 1-9.
Jewell et al., “Pharmacokinetics of RheothRx Injection in Healthy Male Volunteers”,Journal of Pharmaceutical Sciences, vol. 86, No. 7, 1997, pp. 808-812.
Bochot et al., “Liposomes Dispersed Within a Thermosensitive Gel: A new Dosage Form for Ocular Delivery of Oligonucleotides”,Pharmaceutical Research, vol. 15, No. 9, 1998, pp. 1364-1369.
Edsman et al., “Rheological evaluation of poloxamer as an in situ gel for ophthalmic use”,European Journal of Pharmaceutical Sciences, vol. 6, 1998, pp. 105-112.
Kim et al., “Trials of in situ-gelling and mucoadhesive acetaminophen liquid suppository in human subjects”,International Journal of Pharmaceutics, vol. 174, 1998, pp. 201-207.
Brown et al., “Thermorheology of polaxamer 407: effect of alcohols and drugs”,J. Pharm. Pharmacol., vol. 50, Supplement: pp. 159.
Gaisford et al., “Temperature induced aggregation in aqueouos solution of a series of PEO-PPO-PEO copolymers”,International Journal of Pharmaceutics, vol. 174, 1998, pp. 39-46.
Wang et al., “Kinetics of Sol-to-Gel Transition for Poloxamer Polyols”,Journal of Applied Polymer Science, vol. 43, 1991, pp. 283-292.
Stratton et al., “Drug Delivery Matrix Containing Native Protein Precipitates Suspended in a Poloxamer Gel”,Journal of Pharmaceutical Sciences, vol. 86, No. 9, 1997, pp. 1006-1010.

Affiliated with

Also associated with

Rating

Orally administered liquid compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Orally administered liquid compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Orally administered liquid compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3701733